brain

The Supply Brain

Addressing supply chain challenges in cell and gene therapy.

The OrganaBio Blog

Jack Camoratto

Jack Camoratto
Jack has received degrees in biomedical engineering with a focus in biomaterials and tissue from the University of Miami. During his time at UM, Jack conducted research investigating the effects of stem cell-conditioned media on chondrocyte inflammation. Jack brings experience in the healthcare field to OrganaBio from his work at Stryker, where he took part in large-scale manufacturing process development and implementation for surgical robotics systems.

Recent Posts

Simple Science: Cardiac RegenMed

Posted by Jack Camoratto on September 01, 2020

Simple Science: Cardiac Regenerative Medicine

The field of cardiac regenerative medicine is rapidly developing solutions to treat the millions of people around the world affected by cardiac illnesses. The articles summarized in the Simple Science posts below outline a few of the recent advancements in cardiac tissue engineering, disease modeling, and the role of the stem cell secretome in cardiac protection. OrganaBio’s goal in summarizing these complex articles is to translate regenerative medicine articles that excite our scientists into articles that anyone can enjoy, whether they’re looking for information that inspires hope or just looking for a good read. Scientific articles may be written for a research-savvy audience but, in the end, the discoveries they outline affect us all. We hope you enjoy some Simple Science!

Read More
0 Comments // View or add comments

Topics: Allogeneic Cell Therapy, Exosomes, MSCs, iPSCs, Gene Editing

You Need Access to a Robust and Reliable Donor Pool

Posted by Jack Camoratto on June 08, 2020

De-Risking the Path to Cell & Gene Therapy Commercialization Part 1: You Need Access to a Robust and Reliable Donor Pool

Bridging the Gap from R&D to Clinical Translation

When cell and gene therapy researchers step into the lab each morning, we envision transforming what may be an early stage experiment into a clinical success. Therapeutics developers spend years working tirelessly to generate pre-clinical data so that, when the time comes, their Investigational New Drug (IND) application (or equivalent outside the USA) will be accepted by the appropriate regulatory agency, allowing the therapy to enter clinical trials. However, IND approval is just the first of many significant hurdles that therapeutics developers face on the path to commercialization.

Read More
0 Comments // View or add comments

Topics: mesenchymal stromal cells, Immune Cells, Allogeneic Cell Therapy, MSCs, Hematopoietic Stem Cells, donor variability, Starting Materials, supply chain, OrganaBio

All posts
Add a Comment

Recent Posts

Posts by Tag

See all